Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur®), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome

✍ Scribed by P.-A. Regidor; M. Regidor; K. Kato; U.W. Bier; K. Bühler; A.E. Schindler

• Book ID: 117460493
• Publisher: Elsevier Science
• Year: 1997
• Tongue: English
• Weight: 854 KB
• Volume: 73
• Category: Article
• ISSN: 0301-2115
• DOI: 10.1016/s0301-2115(97)02733-4